Moderate-to-severe atopic dermatitis is associated with higher lifetime prevalence of multimorbidity and increased odds of ...
Rocatinlimab, administered subcutaneously, results in clinically meaningful improvements in patients with moderate-to-severe ...
Ruxolitinib cream demonstrated favorable safety and efficacy in pediatric atopic dermatitis, highlighting JAK inhibitors' ...
Kymera Therapeutics receives US FDA Fast Track Designation for KT-621, an oral STAT6 degrader to treat atopic dermatitis: Watertown, Massachusetts Saturday, December 13, 2025, 18: ...
Kymera Therapeutics has announced positive results from its trial of KT-621 to treat patients with moderate to severe atopic ...
Rocatinlimab improved moderate to severe dermatitis in adults, establishing the OX40 receptor as a validated treatment target ...
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase ...
Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics (R) , today announced the close of its $25 million, twice-oversubscribed Series B ...
A real-world analysis published in the Journal of Allergy and Clinical Immunology examined the effectiveness of upadacitinib ...
Advancement to Phase 2 follows positive interim Phase 1b data in Atopic Dermatitis, demonstrating a robust efficacy and safety profileParallel Phase 2a initiated studies evaluating ENV-294, a first-in ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the dosing of the first participant in a global Phase 1/1b ...
Everyday Health on MSN
Atopic dermatitis: What to do if topical steroids aren't helping
Still itching after topical steroids? Here's why your atopic dermatitis symptoms may still be flaring and what you can do about it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback